| No. |
DrugBank |
薬物名（臨床試験情報から抽出） |
KEGG DRUG * | KEGG GENES * |
KEGG PATHWAY |
指定難病告示番号 * |
| 1 | ATL1102 | 1件: Atl1102; | - |
- |
- |
1件: 13 |
| 2 | Abatacept | 27件: Abatacept; Abatacept (aba); Abatacept (aba) + methotrexate (mtx), double-blind (db); Abatacept (bms-188667); Abatacept (iv); Abatacept + csdmard; Abatacept + methotrexate; Abatacept + vaccines; Abatacept injection; Abatacept placebo; Abatacept prefilled syringe; Abatacept sc; Abatacept subcutaneous; Abatacept, rituximab or tocilizumab; Bdmard withdrawal (etanercept, adalimumab, infliximab, certolizumab, golimumab, tozilizumab, abatacept); Bms 188667 (abatacept); Decrease tocilizumab, abatacept; Double-blind abatacept; Intravenous (iv) abatacept; Iv abatacept; Open-label abatacept; Orencia (abatacept); Orencia abatacept; Subcutaneous (sc) abatacept; Subcutaneous abatacept; Subcutaneous(sc) abatacept; Tocilizumab, abatacept; | D03203 |
2件: CD80, CD86 |
12件: Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules (CAMs), Graft-versus-host disease, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Rheumatoid arthritis, Systemic lupus erythematosus, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis |
24件: 11, 13, 19, 41, 44, 46, 49, 50, 51, 53, 55, 60, 65, 84, 93, 96, 97, 107, 164, 222, 271, 284, 285, 300 |
| 3 | Acetaminophen | 8件: Acetaminophen; Acetaminophen tab 650mg; Acetaminophen tablets; Acetaminophen/paracetamol; Oxycodone/acetaminophen; Paracetamol (acetaminophen); Tramadol /acetaminophen; Tramadol hydrochloride + acetaminophen; | D00217 |
2件: PTGS1, PTGS2 |
21件: Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway |
13件: 3, 6, 13, 34, 35, 46, 49, 51, 70, 86, 231, 256, 271 |
| 4 | Acetate | 76件: 11c acetate; 11c-acetate; 20mg/0.5ml glatiramer acetate; 40 mg glatiramer acetate; [n-trans-3-hexenoyl] human growth hormone releasing factor (1-44) acetate; Abiraterone acetate; Acetate; Bazedoxifene acetate; Betamethasone sodium phosphate/betamethasone acetate (celestone® soluspan®), 30 mg im once a day for four days; Caspofungin acetate; Conventional glucocorticoids (immediate release hydrocortisone, cortisone acetate, prednisone, prednisolone, dexamethasone); Cortisone acetate; Cosyntropin acetate; Cyclophosphamide/glatiramer acetate; Delmitide acetate; Depot leuprolide acetate 3.75 mg; Desmopressin acetate; Desmopressin acetate trihydrate; Dirucotide acetate; Experimental glatiramer acetate; Flecainide acetate; Glatiramer acetate; Glatiramer acetate (copaxone®); Glatiramer acetate (db); Glatiramer acetate (ga); Glatiramer acetate (ga) 40 mg; Glatiramer acetate (ol); Glatiramer acetate 150mg enteric coated tablets; Glatiramer acetate 150mg enteric-coated (gastro-resistant) tablets; Glatiramer acetate 20 mg; Glatiramer acetate 20 mg, with mitoxantrone; Glatiramer acetate 20 mg/0.5 ml; Glatiramer acetate 40 mg; Glatiramer acetate injection with oral cetirizine hydrochloride; Glatiramer acetate with minocycline; Glatiramer acetate, (copaxone®); Glatiramer acetate, ifn-beta 1a (im), ifn-beta 1a (subcutaneous), and ifn-beta 1b; Glatiramer acetate, n-acetylcysteine; Gonadorelin acetate and triptorelin acetate; Human interferon beta-1a and glatiramer acetate; Hydrocortisone sodium acetate; L-lysyl-d-prolyl-l-threonine acetate; Lanreotide acetate; Leuprolide acetate (la); Leuprolide acetate 11.25 mg; Leuprolide acetate 3 month depot; Leuprolide acetate 30 mg; Leuprolide acetate 45 mg; Leuprolide acetate depot; Leuprorelin acetate; Leuprorelin acetate 3.75mg injection; Loestrin (norethindrone acetate and ethinyl estradiol); Loestrin 1.5/30 (1.5 mg norethindrone acetate/30 µg ethinyl estradiol); Luphere depot 3.75mg(leuprolide acetate 3.75mg); Lupron (leuprolide acetate); Macimorelin acetate; Megestrol acetate; Megestrol acetate tablet; Nomegestrol acetate; Phosphate and betamethasone acetate, 2 ml.; Plovamer acetate; Prednisolone acetate; Prednisone acetate; Prednisone acetate tablets; Sodium acetate; Sodium-[o-[(2,6-dichlorophenyl)-amino]-phenyl]-acetate; Sotrastaurin (inn) acetate; Tetracosactide acetate; Tocopherol acetate; Tocopheryl acetate; Triptorelin acetate and gonadorelin acetate; Ulipristal acetate; Zinc acetate; Zinc acetate (20mg/d); Zinc acetate dihydrate; Zuretinol acetate; | - |
- |
- |
40件: 1, 2, 6, 10, 13, 35, 40, 46, 49, 51, 60, 64, 70, 71, 73, 75, 76, 78, 81, 83, 85, 86, 88, 90, 96, 97, 113, 145, 156, 162, 171, 206, 222, 224, 225, 235, 265, 288, 298, 299 |
| 5 | Acetazolamide | 2件: Acetazolamide; Acetazolamide sandoz 250; | D00218
D01196 |
13件: CA1, CA12, CA13, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA8, CA9 |
7件: Bile secretion, Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Nitrogen metabolism, Pancreatic secretion, Proximal tubule bicarbonate reclamation |
6件: 13, 90, 115, 155, 225, 230 |
| 6 | Acetic acid C-11 | - | - |
- |
- |
3件: 13, 86, 88 |
| 7 | Acetylcysteine | 8件: Acetylcysteine; Acetylcysteine sodium; Glatiramer acetate, n-acetylcysteine; N acetylcysteine; N-acetylcysteine; N-acetylcysteine (nac); N-acetylcysteine capsule; N-acetylcysteine, (nac); | D00221 |
- |
- |
16件: 6, 13, 19, 20, 49, 51, 58, 85, 94, 96, 97, 111, 164, 233, 298, 299 |
| 8 | Acetylsalicylic acid | 2件: Acetylsalicylic acid; Acetylsalicylic acid at 1st visit,; | D00109 |
2件: PTGS1, PTGS2 |
21件: Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway |
10件: 13, 22, 34, 46, 49, 51, 86, 113, 158, 231 |
| 9 | Activated charcoal | - | D03251 |
- |
- |
8件: 6, 13, 46, 85, 86, 96, 97, 298 |
| 10 | Acyclovir | 1件: Acyclovir; | D00222 |
- |
- |
5件: 13, 28, 46, 53, 60 |
| 11 | Adenosine | 4件: 2-cda, 2-chloro-2’-deoxy-beta-d-adenosine; 2-cda, 2-chloro-2’-deoxy-ß-d-adenosine; Adenosine; Autologous ex vivo gene therapy products based on the efs lv encoding for the human adenosine deaminase (ada) gene (efs-ada lv); | D00045 |
4件: ADORA1, ADORA2A, ADORA2B, ADORA3 |
12件: Alcoholism, Calcium signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Sphingolipid signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
5件: 13, 46, 53, 58, 65 |
| 12 | Alemtuzumab | 18件: Alemtuzumab; Alemtuzumab (already received by alemtuzumab cohort between 1991 and 1994; Alemtuzumab (already received by alemtuzumab cohort between 1991 and 1994); Alemtuzumab (campath ); Alemtuzumab (campath); Alemtuzumab (gz402673); Alemtuzumab 0.2 mg; Alemtuzumab 0.3 mg; Alemtuzumab 12 mg; Alemtuzumab 24 mg; Alemtuzumab and rituximab; Alemtuzumab gz402673; Alemtuzumab immunotherapy; Alemtuzumab injection [lemtrada]; Alemtuzumab, rituximab; Filgrastim, alemtuzumab; Transplant conditioning with mobilization and alemtuzumab; Transplant preparative regimen of alemtuzumab, fludarabine, thiotepa, and melphalan; | D02802 |
- |
- |
17件: 13, 15, 19, 20, 46, 49, 51, 60, 63, 65, 85, 96, 164, 234, 284, 285, 326 |
| 13 | Alfuzosin | 1件: Alfuzosin; | D01692
D07124 |
1件: ADRA1A |
7件: AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway |
1件: 13 |
| 14 | Amantadine | 10件: 240mg amantadine hcl er tablets; 320mg amantadine hcl er tablets; Ads-5102 (extended release amantadine hcl); Amantadine; Amantadine 300 mg; Amantadine hcl er; Amantadine hcl extended release; Amantadine hydrochloride; Amantadine sulfate; Pk-merz® 200mg/500ml inj(amantadine) , normal saline 500ml inj; | D00777
D07441 |
5件: GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D |
17件: Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Rap1 signaling pathway, Ras signaling pathway, Systemic lupus erythematosus, cAMP signaling pathway |
4件: 6, 8, 13, 127 |
| 15 | Amiloride | 6件: Amiloride; Amiloride hcl; Amiloride hydrochloride; Amiloride hydrochloride, 2 h2o; Amiloride solution for inhalation; Hydrochlorothiazide/amiloride; | D00649
D07447 |
3件: SCNN1A, SCNN1B, SCNN1G |
2件: Aldosterone-regulated sodium reabsorption, Taste transduction |
3件: 13, 225, 299 |
| 16 | Anakinra | 8件: Anakinra; Anakinra (kineret®); Anakinra (r-methuil-1ra); Anakinra / kineret; Anakinra and peg stnf-r1; Kineret® (anakinra); Kineret® or anakinra; Response to anakinra associated with methotrexate; | D02934 |
2件: IL1R1, IL1R2 |
15件: Amoebiasis, Cytokine-cytokine receptor interaction, Fluid shear stress and atherosclerosis, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Inflammatory mediator regulation of TRP channels, MAPK signaling pathway, NF-kappa B signaling pathway, Osteoclast differentiation, Pathogenic Escherichia coli infection, Prostate cancer, Shigellosis, Th17 cell differentiation, Transcriptional misregulation in cancer |
17件: 2, 13, 15, 19, 37, 41, 46, 49, 50, 56, 65, 84, 86, 106, 107, 266, 299 |
| 17 | Arbaclofen | 7件: Arbaclofen; Arbaclofen er tablets; Arbaclofen extended release tablets; Arbaclofen placarbil; Arbaclofen placarbil 15 mg bid; Arbaclofen placarbil 30 mg bid; Arbaclofen placarbil 45 mg bid; | D09791 |
2件: GABBR1, GABBR2 |
7件: Estrogen signaling pathway, GABAergic synapse, GnRH secretion, Morphine addiction, Neuroactive ligand-receptor interaction, Taste transduction, cAMP signaling pathway |
2件: 13, 206 |
| 18 | Arbaclofen Placarbil | 4件: Arbaclofen placarbil; Arbaclofen placarbil 15 mg bid; Arbaclofen placarbil 30 mg bid; Arbaclofen placarbil 45 mg bid; | D08861 |
2件: GABBR1, GABBR2 |
7件: Estrogen signaling pathway, GABAergic synapse, GnRH secretion, Morphine addiction, Neuroactive ligand-receptor interaction, Taste transduction, cAMP signaling pathway |
1件: 13 |
| 19 | Armodafinil | 1件: Armodafinil; | D03215 |
1件: SLC6A3 |
6件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Parkinson disease, Synaptic vesicle cycle |
3件: 6, 13, 84 |
| 20 | Ascorbic acid | 4件: 2l polyethylene glycol/ascorbic acid; Ascorbic acid; Ascorbic acid (vitamin c); Ascorbic acid vit c; | D00018 |
- |
- |
13件: 10, 13, 49, 62, 86, 96, 97, 192, 206, 211, 212, 254, 284 |
| 21 | Aspartic acid | - | D00013 |
- |
- |
3件: 13, 75, 299 |
| 22 | Atacicept | 5件: Atacicept; Atacicept 150 mg; Atacicept 25 mg; Atacicept 75 mg; Atacicept 75 milligram (mg); | D09704 |
2件: TNFSF13, TNFSF13B |
4件: Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis |
4件: 13, 46, 49, 66 |
| 23 | Atomoxetine | 1件: Atomoxetine; | D02574
D07473 |
1件: SLC6A2 |
1件: Synaptic vesicle cycle |
3件: 6, 8, 13 |
| 24 | Atorvastatin | 9件: Atorvastatin; Atorvastatin 10mg; Atorvastatin 20mg; Atorvastatin calcium; Atorvastatin tablet 20 mg; Interferon beta treatment to add-on atorvastatin treatment; Interferon beta-1b/atorvastatin group; Lisinopril, losartan, and atorvastatin; Untreated to atorvastatin treatment; | D00258
D00887
D07474 |
1件: HMGCR |
4件: AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis |
17件: 13, 46, 49, 51, 58, 63, 79, 84, 88, 93, 96, 160, 222, 225, 265, 271, 299 |
| 25 | Azathioprine | 33件: 5-asa, prednisone, azathioprine or remicade; Azathioprine; Azathioprine (aza); Azathioprine (aza) or 6-mercaptopurine (6-mp); Azathioprine 25 mg; Azathioprine and allopurinol; Azathioprine in case of endoscopic recurrence; Azathioprine individualised dose; Azathioprine or 6-mercaptopurine; Azathioprine or adalimumab and infliximab; Azathioprine or mesalazine; Azathioprine or methotrexate; Azathioprine or mycophenolate mofetil; Azathioprine weight-based dose; Azathioprine+enteral nutrition; Azathioprine/prednisone; Combination of protein a immunoadsorption, rituximab, dexamethasone plus azathioprine; Continuation of azathioprine; Corticosteroid and azathioprine; Cyclophosphamide, azathioprine,prednisone,methylprednisolone; Cyclophosphamide-prednisone-azathioprine; Early immunosuppressants (azathioprine, methotrexate); Immunosuppressive regime (azathioprine, mycophenolate mofetil or methotrexate); Infliximab and azathioprine combination at week 0; Infliximab and azathioprine combination at week 14; Infliximab with azathioprine (iifx + aza); Infliximab+azathioprine; Infliximab, azathioprine; Overencapsulated azathioprine (imuran) 50 mg tablet; Prednisone - azathioprine; Products containing azathioprine or 6-mercaptopurine; Rituximab (rtx) and azathioprine (aza); Steroids plus azathioprine; | D00238
D03033 |
- |
- |
18件: 11, 13, 19, 35, 42, 43, 44, 45, 46, 49, 65, 66, 85, 94, 95, 96, 97, 162 |
| 26 | Azithromycin | 10件: Azithromycin; Azithromycin (zitromax°); Azithromycin + metronidazole; Azithromycin + n-acetylcystein + inhaled corticosteroid; Azithromycin 250 mg tablets; Azithromycin 250mg capsule; Azithromycin 500 mg film-coated tablet; Azithromycin dihydrate; Po azithromycin; Study medication, azithromycin; | D02134
D06390
D07486 |
- |
- |
6件: 13, 84, 85, 96, 228, 299 |
| 27 | Baclofen | 5件: Aert, (r)-baclofen; Baclofen; Baclofen 20 mg; Baclofen ir; Rs-baclofen; | D00241 |
2件: GABBR1, GABBR2 |
7件: Estrogen signaling pathway, GABAergic synapse, GnRH secretion, Morphine addiction, Neuroactive ligand-receptor interaction, Taste transduction, cAMP signaling pathway |
5件: 2, 10, 13, 18, 149 |
| 28 | Baminercept | 3件: Baminercept; Baminercept alfa; Baminercept alfa (bg9924); | D08866 |
1件: LTB |
3件: Cytokine-cytokine receptor interaction, NF-kappa B signaling pathway, Rheumatoid arthritis |
4件: 13, 46, 53, 97 |
| 29 | Bazedoxifene | 2件: Bazedoxifene; Bazedoxifene acetate; | D03062 |
- |
- |
1件: 13 |
| 30 | Beta carotene | 2件: Beta carotene; Beta carotene from dunaliella algae; | D03101 |
- |
- |
2件: 13, 96 |
| 31 | Beta-Alanine | 2件: Beta-alanine; Beta-alanine supplementation; | D07561 |
- |
- |
1件: 13 |
| 32 | Bevacizumab | 4件: Bevacizumab; Bevacizumab (avastin) and imatinib mesylate (gleevec); Bevacizumab (genitical recombination); Submucosal bevacizumab; | D06409 |
1件: VEGFA |
21件: AGE-RAGE signaling pathway in diabetic complications, Bladder cancer, EGFR tyrosine kinase inhibitor resistance, Fluid shear stress and atherosclerosis, Focal adhesion, HIF-1 signaling pathway, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, MAPK signaling pathway, MicroRNAs in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Relaxin signaling pathway, Renal cell carcinoma, Rheumatoid arthritis, VEGF signaling pathway |
9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 |
| 33 | Bexarotene | 1件: Bexarotene; | D03106 |
3件: RXRA, RXRB, RXRG |
15件: Adipocytokine signaling pathway, Bile secretion, Gastric cancer, Hepatitis C, Non-alcoholic fatty liver disease (NAFLD), Non-small cell lung cancer, PI3K-Akt signaling pathway, PPAR signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Small cell lung cancer, Th17 cell differentiation, Thyroid cancer, Thyroid hormone signaling pathway, Transcriptional misregulation in cancer |
2件: 13, 75 |
| 34 | Biotin | 2件: Biotin; D-biotin; | D00029 |
- |
- |
3件: 2, 13, 20 |
| 35 | Bisacodyl | 1件: Bisacodyl; | D00245 |
- |
- |
1件: 13 |
| 36 | Borage oil | 2件: Borage oil; Borage oil 20% gla; | - |
- |
- |
1件: 13 |
| 37 | Bosentan | 14件: Bosentan; Bosentan (tracleer); Bosentan 125 mg; Bosentan 62.5 mg; Bosentan administration; Bosentan and sildenafil; Bosentan group; Bosentan monohydrat; Bosentan monohydrate; Bosentan mylan; Bosentan, ambrisentan; Era and pde-5i (sildenafil, tadalafil, bosentan, macitentan); Sildenafil 20mg and bosentan 62.5mg; Sildenafil singly or in association with bosentan; | D01227
D07538 |
2件: EDNRA, EDNRB |
9件: Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
10件: 13, 41, 47, 51, 84, 85, 86, 88, 210, 211 |
| 38 | Botulinum toxin type A | 3件: Botulinum toxin type a; Botulinum toxin type a (nabota®) injection into the gastrocnemius muscle; Clostridium botulinum toxin type a; | D00783 |
1件: SNAP25 |
2件: Insulin secretion, Synaptic vesicle cycle |
13件: 2, 5, 6, 7, 13, 15, 17, 36, 51, 70, 113, 149, 226 |
| 39 | CDP323 | 1件: Cdp323; | - |
- |
- |
1件: 13 |
| 40 | Calcium | 25件: Amorphous calcium carbonate; Ascal(r) / carbasalate calcium; Atorvastatin calcium; Calcitriol & calcium; Calcium; Calcium and cholecalciferol; Calcium carbonate; Calcium carbonate and alphacalcidol; Calcium channel blockers; Calcium channel blockers (amlodipine, azelnidipine); Calcium citrate; Calcium citrate with vitamin d2; Calcium gluconate; Calcium lactate; Calcium levofolinate; Calcium rosuvastatin; Calcium, dietary; Carbasalate calcium; Crestor tablets (calcium rosuvastatin) film-coated tablets; Crystalline calcium supplements; Ibandronate+alfacalcidol+calcium; Low molecular weight heparin calcium injection; Rosuvastatin calcium; Symptomatic treatment (converting enzyme inhibitor, angiotensin ii, anti-renin, aldosterone antagonist diuretic, beta blocker, calcium inhibitor, statin); Vidofludimus calcium; | - |
- |
- |
24件: 6, 13, 19, 46, 49, 51, 65, 68, 75, 79, 84, 93, 94, 95, 96, 97, 214, 215, 222, 224, 235, 265, 298, 299 |
| 41 | Calcium Carbonate | 3件: Amorphous calcium carbonate; Calcium carbonate; Calcium carbonate and alphacalcidol; | D00932
D10802 |
- |
- |
7件: 13, 19, 46, 75, 96, 235, 299 |
| 42 | Cannabidiol | 6件: Cannabidiol; Cannabidiol (cbd); Cannabidiol / dronabinol capsule 5 mg+2,5 mg; Cannabidiol capsule 5 mg; Cannabidiol oral solution; Cannabidiol tablet 10 mg; | D10915 |
2件: CNR1, CNR2 |
4件: Neuroactive ligand-receptor interaction, Rap1 signaling pathway, Retrograde endocannabinoid signaling, Thermogenesis |
14件: 2, 6, 13, 46, 95, 96, 97, 140, 144, 145, 157, 158, 193, 271 |
| 43 | Carbidopa | 60件: Accordion pill carbidopa/levodopa; Accordion pill™ carbidopa/levodopa; Accordion pill™ carbidopa/levodopa 50/400 mg; Accordion pill™ carbidopa/levodopa 50/500 mg; Capsules containing: carbidopa (25 mg), levodopa (100 mg), entacapone (200 mg); Carbidopa; Carbidopa 20 mg; Carbidopa 27.5 mg; Carbidopa 65 mg capsule; Carbidopa and levodopa 25mg/100mg; Carbidopa fu; Carbidopa levodopa; Carbidopa monohydrate; Carbidopa, levodopa, entacapone; Carbidopa- levodopa; Carbidopa-levodopa; Carbidopa/l-dopa; Carbidopa/l-dopa/entacapone; Carbidopa/levodopa; Carbidopa/levodopa, immediate release; Carbidopa/levodopa/entacapone; Comparator: carbidopa; Continuous intrajejunal infusion of levodopa-carbidopa; Controlled-release levodopa / carbidopa; Entacapone and carbidopa; Immediate release carbidopa/levodopa; Immediate release carbidopa/levodopa 25/100 mg; Levodopa and carbidopa; Levodopa and carbidopa sc solution; Levodopa and carbidopa solution for sc administration; Levodopa carbidopa (lc) oral encapsulated immediate release (ir) tablets; Levodopa carbidopa intestinal gel (lcig); Levodopa, carbidopa, entacapone; Levodopa, carbidopa, odm-104; Levodopa-carbidopa; Levodopa-carbidopa (lc) oral encapsulated immediate release (ir) tablets; Levodopa-carbidopa immediate release (lc-ir) tablets; Levodopa-carbidopa intestinal gel; Levodopa-carbidopa multilayer extended release tablet; Levodopa-carbidopa xl tablet (m); Levodopa-carbidopa-entacapone; Levodopa/carbidopa; Levodopa/carbidopa (4:1); Levodopa/carbidopa (sinemet); Levodopa/carbidopa 100/25; Levodopa/carbidopa hydrate; Levodopa/carbidopa solution; Levodopa/carbidopa(200mg/50mg); Levodopa/carbidopa/entacapone; Nd0612 (levodopa/carbidopa solution); Odm-101 105mg carbidopa; Odm-101 65mg carbidopa; Oral levodopa and carbidopa; Oral levodopa/carbidopa; Sinemet (levodopa/carbidopa); Sinemet plus (levodopa/carbidopa); Sinemet® controlled release (carbidopa/levodopa); Stalevo (levodopa/ carbidopa/ entacapone); Stalevo (levodopa/carbidopa/entacapona); Xp21279 and carbidopa (experimental); | D00558 |
1件: DDC |
9件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism |
8件: 2, 4, 6, 13, 17, 90, 164, 201 |
| 44 | Carbonate ion | - | - |
- |
- |
10件: 2, 13, 17, 19, 46, 75, 96, 127, 235, 299 |
| 45 | Carmustine | 2件: Carmustine; Carmustine, etoposide, cytarabine, and melphalan (beam); | D00254 |
- |
- |
5件: 11, 13, 14, 28, 60 |
| 46 | Carnosine | 3件: Carnosine; Carnosine supplementation; Carnosine, capsulle, 2 g/day, 8 weeks; | - |
- |
- |
2件: 6, 13 |
| 47 | Cetirizine | 4件: Antihistamine (cetirizine or equivalent); Cetirizine; Cetirizine hydrochloride; Glatiramer acetate injection with oral cetirizine hydrochloride; | D00664
D07662 |
1件: HRH1 |
3件: Calcium signaling pathway, Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction |
2件: 13, 35 |
| 48 | Chloride ion | - | - |
- |
- |
17件: 6, 11, 13, 14, 34, 46, 51, 96, 97, 127, 168, 193, 227, 228, 288, 297, 299 |
| 49 | Chloroxylenol | - | D03473 |
- |
- |
4件: 6, 13, 46, 168 |
| 50 | Cholecalciferol | 9件: 5000 iu of cholecalciferol; Calcium and cholecalciferol; Cholecalciferol; Cholecalciferol (vitamin d3); Cholecalciferol 10,000 iu; Cholecalciferol 400 iu; Cholecalciferol and c. xanthorrhiza; Cholecalciferol concentrate; Cholecalciferol, vitamin d3; | D00188 |
1件: VDR |
4件: Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis |
15件: 6, 13, 19, 20, 34, 46, 49, 53, 60, 65, 96, 97, 228, 298, 299 |
| 51 | Cholestyramine | 1件: Cholestyramine; | - |
- |
- |
5件: 13, 79, 93, 254, 297 |
| 52 | Cisapride | 1件: Cisapride; | D00274
D02092 |
3件: HTR2A, HTR3A, HTR4 |
7件: Calcium signaling pathway, Gap junction, Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction, Serotonergic synapse, Taste transduction, cAMP signaling pathway |
1件: 13 |
| 53 | Cladribine | 4件: Cladribine; Cladribine 3.5 mg/kg; Cladribine 5.25 mg/kg; Cladribine tablets; | D01370 |
1件: RRM1 |
5件: Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism |
2件: 13, 94 |
| 54 | Clemastine | 1件: Clemastine; | D00666
D03535 |
1件: HRH1 |
3件: Calcium signaling pathway, Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction |
1件: 13 |
| 55 | Clostridium botulinum | 2件: Clostridium botulinum; Clostridium botulinum toxin type a; | - |
- |
- |
1件: 13 |
| 56 | Coconut | 3件: Coconut; Coconut oil; Coconut oil and epigallocatechin gallate; | - |
- |
- |
1件: 13 |
| 57 | Coconut oil | 2件: Coconut oil; Coconut oil and epigallocatechin gallate; | D05326 |
- |
- |
1件: 13 |
| 58 | Coenzyme M | - | - |
- |
- |
9件: 13, 44, 45, 49, 51, 60, 65, 96, 164 |
| 59 | Corticotropin | 8件: Corticotropin; Corticotropin releasing hormone; Corticotropin-releasing hormone; H.p. acthar gel (repository corticotropin injection); H.p. acthar® gel (repository corticotropin injection); Ovine corticotropin-releasing hormone (ocrh); Repository corticotropin injection; Repository corticotropin injection -treatment extension; | D00146 |
1件: MC2R |
5件: Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway |
12件: 2, 13, 46, 49, 50, 66, 75, 78, 84, 145, 193, 222 |
| 60 | Cranberry | 1件: Cranberry; | - |
- |
- |
1件: 13 |
| 61 | Creatine | 4件: Creatine; Creatine monohydrate; Creatine-13c; Pyruvate, creatine, niacinamide; | - |
- |
- |
12件: 1, 2, 5, 6, 8, 13, 46, 49, 50, 113, 156, 201 |
| 62 | Curcumin | 5件: Bio-enhanced curcumin soft gelatin capsule; Curcumin; Curcumin (longvida™); Curcumin supplement; Ifn beta 1 a + curcumin (bcm 95); | - |
- |
- |
10件: 13, 46, 49, 67, 74, 94, 96, 97, 139, 299 |
| 63 | Cyanocobalamin | - | D00166
D03615
D03616
D03617 |
- |
- |
12件: 6, 13, 49, 62, 86, 96, 97, 201, 229, 254, 284, 299 |
| 64 | Cyclophosphamide | 48件: Busulfan, cyclophosphamide, antithymocyte globulin; Busulfan, cyclophosphamide, atg; Busulfan, cyclophosphamide, atg, gcsf; Busulfan, cyclophosphamide, thymoglobulin, fludarabine (conditioning regimen); Busulfan, fludarabine, & cyclophosphamide with immunosuppression with atg and cyclosporine.; Campath, fludarabine, cyclophosphamide; Cyclophosphamide; Cyclophosphamide (cy); Cyclophosphamide (cy) (plan 1); Cyclophosphamide (cy) (plan 2); Cyclophosphamide (drug); Cyclophosphamide + pred; Cyclophosphamide 100mg; Cyclophosphamide 150mg; Cyclophosphamide 30; Cyclophosphamide 40; Cyclophosphamide 50mg; Cyclophosphamide 50mg oral tablet; Cyclophosphamide and atg; Cyclophosphamide and steroids; Cyclophosphamide dose level 1; Cyclophosphamide dose level 2; Cyclophosphamide dose level 3; Cyclophosphamide dose level 4; Cyclophosphamide monohydrate; Cyclophosphamide post transplant; Cyclophosphamide(ctx); Cyclophosphamide, azathioprine,prednisone,methylprednisolone; Cyclophosphamide, bortezomib, dexamethasone; Cyclophosphamide, bortezomib, dexamethasone plus daratumumab; Cyclophosphamide, fludarabine; Cyclophosphamide, fludarabine , thymoglobulin; Cyclophosphamide, fludarabine, rabbit atg; Cyclophosphamide, fludarabine, thymoglobulin; Cyclophosphamide,campath ih and tbi; Cyclophosphamide,cyclosporine a; Cyclophosphamide-prednisone-azathioprine; Cyclophosphamide/glatiramer acetate; Fludarabine, cyclophosphamide; Haploidentical hsct using tbi free regimen, ''atg'' with ''post transplant cyclophosphamide''; High-dose cyclophosphamide; Iv cyclophosphamide; Lenalidomide, dexamethasone and cyclophosphamide; Prednisone and cyclophosphamide; Prednisone plus cyclophosphamide; Prednisone, cyclophosphamide; Rituximab and cyclophosphamide iv; Thalidomide, cyclophosphamide and prednisone; | D00287
D07760 |
- |
- |
43件: 13, 14, 16, 19, 20, 26, 28, 35, 36, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 52, 56, 60, 61, 62, 65, 66, 84, 85, 93, 96, 162, 164, 172, 222, 224, 265, 274, 283, 284, 285, 288, 326, 331 |
| 65 | Cytarabine | 2件: Carmustine, etoposide, cytarabine, and melphalan (beam); Cytarabine; | D00168
D03046
D03637 |
- |
- |
6件: 11, 13, 14, 25, 49, 60 |
| 66 | D-Aspartic Acid | - | - |
- |
- |
1件: 13 |
| 67 | D-glucose | 3件: 2-deoxy-2 [f-18] fluoro-2-d-glucose; [18f]fluoro-2-deoxy-2-d-glucose; D-glucose; | D00009 |
- |
- |
6件: 6, 13, 49, 86, 88, 299 |
| 68 | Daclizumab | 7件: Biib019 (daclizumab); Daclizumab; Daclizumab (anti-cd25 humanized monoclonal antibody); Daclizumab high yield process; Daclizumab hyp; Daclizumab hyp (dac hyp); Daclizumab with greek suufix; | D03639 |
1件: IL2RA |
11件: Cytokine-cytokine receptor interaction, Endocytosis, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, JAK-STAT signaling pathway, Measles, PI3K-Akt signaling pathway, Pathways in cancer, Th1 and Th2 cell differentiation, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor |
7件: 13, 56, 60, 65, 97, 283, 284 |
| 69 | Dalfampridine | 5件: Dalfampridine; Dalfampridine er; Dalfampridine-er 10mg; Dalfampridine-er 5mg; Sustained-release oral dalfampridine; | D04127 |
2件: KCNA4, KCND2 |
3件: Cortisol synthesis and secretion, Cushing syndrome, Serotonergic synapse |
3件: 3, 4, 13 |
| 70 | Darifenacin | 2件: Darifenacin; Oxybutynin and darifenacin; | D01699
D03654 |
1件: CHRM3 |
9件: Calcium signaling pathway, Cholinergic synapse, Gastric acid secretion, Insulin secretion, Neuroactive ligand-receptor interaction, Pancreatic secretion, Regulation of actin cytoskeleton, Salivary secretion, Taste transduction |
2件: 6, 13 |
| 71 | Dexamethasone | 35件: Bortezomib/dexamethasone (bd), followed by autologous stc & maintenance bortezomib/dexamethasone; Bupivacaine/epinephrine/dexamethasone; Combination of protein a immunoadsorption, rituximab, dexamethasone plus azathioprine; Control intervention (no dexamethasone); Conventional glucocorticoids (immediate release hydrocortisone, cortisone acetate, prednisone, prednisolone, dexamethasone); Cyclophosphamide, bortezomib, dexamethasone; Cyclophosphamide, bortezomib, dexamethasone plus daratumumab; Dexamethasone; Dexamethasone (1 cycle); Dexamethasone (4 cycles); Dexamethasone (50mg 1dd6, 3 consecutive days/month); Dexamethasone 0,5mg; Dexamethasone 0.5mg tablet; Dexamethasone 21-phosphate; Dexamethasone 2mg tablets; Dexamethasone abcur; Dexamethasone and rituximab; Dexamethasone parotid irrigation; Dexamethasone sodium phosphate; Dexamethasone sodium phosphate 250 mg/ 10 ml; Dexamethasone sodium phosphate 250 mg/10 ml solution; Dexamethasone sodium phosphate ph. eur.; Dexamethasone soduim phosphate; Dexamethasone, 40 mg; High dose dexamethasone pulses; Intraarticular dexamethasone; Intravenous dexamethasone 1 mg; Lenalidomide and dexamethasone; Lenalidomide+dexamethasone; Lenalidomide, dexamethasone; Lenalidomide, dexamethasone and cyclophosphamide; Melphalan, thalidomide and dexamethasone; Mmf and dexamethasone; Peri-neural dexamethasone 1 mg; Pomalidomide and dexamethasone; | D00292
D00975
D01510
D01615
D01632
D01948
D02174
D02591
D02592 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
20件: 13, 16, 28, 35, 46, 53, 63, 65, 70, 74, 75, 81, 83, 84, 90, 96, 97, 222, 296, 299 |
| 72 | Dexchlorpheniramine | 1件: Dexchlorpheniramine; | D07803 |
1件: HRH1 |
3件: Calcium signaling pathway, Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction |
1件: 13 |
| 73 | Dexrazoxane | 2件: Dexrazoxane; Dexrazoxane (drz) plus mitoxantrone (mx); | D03730 |
2件: TOP2A, TOP2B |
1件: Platinum drug resistance |
1件: 13 |
| 74 | Dextromethorphan | 9件: Dextromethorphan; Dextromethorphan 30 mg; Dextromethorphan and caffeine; Dextromethorphan hbr and quinidine sulfate; Dextromethorphan hydrobromide; Dextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mg; Dextromethorphan hydrobromide 30 mg and quinidine sulfate 10 mg; Dextromethorphan/quinidine 20mg/10mg (dm/q 20mg/10mg); Dimebon + dextromethorphan; | D00848
D03742
D03744 |
5件: GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D |
17件: Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Rap1 signaling pathway, Ras signaling pathway, Systemic lupus erythematosus, cAMP signaling pathway |
9件: 2, 6, 8, 13, 46, 78, 96, 97, 156 |
| 75 | Diclofenac | 9件: Comparator: diclofenac; Comparator: diclofenac sodium; Diclofenac; Diclofenac + omeprazole; Diclofenac 50 milligrams; Diclofenac natrium pch retard tablet mga 75mg; Diclofenac sodium; Diclofenac sodium topical gel; Diclofenac sr; | D00903
D00904
D07816 |
2件: PTGS1, PTGS2 |
21件: Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway |
4件: 13, 34, 46, 271 |
| 76 | Dimethicone | - | D01540 |
- |
- |
2件: 13, 96 |
| 77 | Dimethyl fumarate | 4件: Dimethyl fumarate; Dimethyl fumarate (dmf); Dimethyl fumarate [dmf]; Tecifdera (dimethyl fumarate); | D03846 |
1件: KEAP1 |
4件: Fluid shear stress and atherosclerosis, Hepatocellular carcinoma, Pathways in cancer, Ubiquitin mediated proteolysis |
5件: 13, 46, 49, 51, 86 |
| 78 | Diroximel fumarate | 2件: Diroximel fumarate; Diroximel fumarate (drf); | D11154 |
- |
- |
1件: 13 |
| 79 | Dirucotide | 2件: Dirucotide; Dirucotide acetate; | D09396 |
- |
- |
1件: 13 |
| 80 | Docusate | - | D00305 |
- |
- |
7件: 13, 62, 86, 96, 97, 254, 284 |
| 81 | Domperidone | 3件: Domperidone; Domperidone (drug); Levodopa and domperidone; | D01745
D07868 |
1件: DRD2 |
8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
5件: 6, 13, 17, 51, 230 |
| 82 | Donepezil | 4件: Donepezil; Donepezil hci (drug); Donepezil hydrochloride; Donepezil sandoz; | D00670
D07869 |
1件: ACHE |
2件: Cholinergic synapse, Glycerophospholipid metabolism |
9件: 5, 6, 13, 46, 78, 124, 127, 156, 206 |
| 83 | Doxycycline | 7件: Antimicrobial therapy: co-trimoxazole or doxycycline; Doxycycline; Doxycycline 100 mg capsules; Doxycycline hyclate; Doxycycline hyclate ph.eur; Interferon beta 1a, oral doxycycline; Treatment with systemic therapy (doxycycline); | D00307
D02129
D03903
D03904
D07876 |
- |
- |
15件: 13, 23, 28, 46, 84, 85, 89, 96, 97, 158, 162, 167, 227, 280, 299 |
| 84 | Dronabinol | 4件: Cannabidiol / dronabinol capsule 5 mg+2,5 mg; Dronabinol; Dronabinol capsule 2,5 mg; Dronabinol capsule 2.5. mg; | D00306 |
2件: CNR1, CNR2 |
4件: Neuroactive ligand-receptor interaction, Rap1 signaling pathway, Retrograde endocannabinoid signaling, Thermogenesis |
5件: 2, 13, 46, 271, 298 |
| 85 | Duloxetine | 3件: Duloxetine; Duloxetine hydrochloride; Duloxetine hydrochloride (hci); | D01179
D07880 |
2件: SLC6A2, SLC6A4 |
2件: Serotonergic synapse, Synaptic vesicle cycle |
3件: 6, 13, 49 |
| 86 | Dydrogesterone | 1件: Dydrogesterone; | D01217 |
1件: PGR |
4件: Breast cancer, Estrogen signaling pathway, Oocyte meiosis, Progesterone-mediated oocyte maturation |
1件: 13 |
| 87 | Eculizumab | 4件: Abp 959 - biosimilar to eculizumab; Eculizumab; Sb12 (proposed eculizumab biosimilar); Soliris (eculizumab); | D03940 |
1件: C5 |
7件: Complement and coagulation cascades, Herpes simplex virus 1 infection, Neuroactive ligand-receptor interaction, Pertussis, Prion diseases, Staphylococcus aureus infection, Systemic lupus erythematosus |
7件: 11, 13, 14, 62, 109, 222, 223 |
| 88 | Efalizumab | 1件: Efalizumab; | D03959 |
1件: ITGAL |
11件: Cell adhesion molecules (CAMs), Epstein-Barr virus infection, Human T-cell leukemia virus 1 infection, Leukocyte transendothelial migration, Malaria, Natural killer cell mediated cytotoxicity, Rap1 signaling pathway, Regulation of actin cytoskeleton, Rheumatoid arthritis, Staphylococcus aureus infection, Viral myocarditis |
9件: 11, 13, 37, 46, 49, 53, 61, 95, 96 |
| 89 | Elezanumab | 1件: Elezanumab; | D11355 |
1件: RGMA |
2件: Axon guidance, TGF-beta signaling pathway |
1件: 13 |
| 90 | Epigallocatechin | 5件: Coconut oil and epigallocatechin gallate; Epigallocatechin; Epigallocatechin gallate; Epigallocatechin-3-gallate (egcg); Epigallocatechin-gallate; | - |
- |
- |
4件: 13, 28, 85, 113 |
| 91 | Epigallocatechin gallate | 2件: Coconut oil and epigallocatechin gallate; Epigallocatechin gallate; | - |
- |
- |
8件: 6, 13, 17, 28, 85, 113, 206, 299 |
| 92 | Epinephrine | 4件: Bupivacaine/epinephrine/dexamethasone; Epinephrine; Lap tap bupivacaine/epinephrine; Us tap bupivacaine/epinephrine; | D00095
D00996
D02149 |
9件: ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3 |
13件: AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Dilated cardiomyopathy (DCM), Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Thermogenesis, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
9件: 6, 13, 46, 86, 96, 168, 226, 231, 256 |
| 93 | Erythropoietin | 4件: Erythropoietin; Erythropoietin human recombinant (eporh); Recombinant human erythropoietin; Recombinant human erythropoietin(rhepo); | D03231 |
1件: EPOR |
5件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer |
9件: 2, 6, 13, 22, 46, 47, 70, 95, 96 |
| 94 | Escitalopram | 3件: Escitalopram; Escitalopram oxalate antidepressant; Oral escitalopram; | D02567
D07704
D07913 |
1件: SLC6A4 |
2件: Serotonergic synapse, Synaptic vesicle cycle |
3件: 2, 6, 13 |
| 95 | Estradiol | 8件: 5% lidocaine/5 mg/ml estradiol compound cream; Estradiol; Estradiol 2 mg; Estradiol hemihydrate; Ethinyl estradiol; Loestrin (norethindrone acetate and ethinyl estradiol); Loestrin 1.5/30 (1.5 mg norethindrone acetate/30 µg ethinyl estradiol); Ortho-cyclen, ethinyl estradiol/norgestimate, 0.035 mg/0.250 mg; | D00105
D01413
D01617
D01953
D04061
D04063
D04064
D04065 |
2件: ESR1, ESR2 |
9件: Breast cancer, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, GnRH secretion, Pathways in cancer, Prolactin signaling pathway, Proteoglycans in cancer, Thyroid hormone signaling pathway |
5件: 13, 46, 49, 226, 299 |
| 96 | Estriol | 2件: Estriol; Vaginal estriol; | D00185
D01986 |
2件: ESR1, ESR2 |
9件: Breast cancer, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, GnRH secretion, Pathways in cancer, Prolactin signaling pathway, Proteoglycans in cancer, Thyroid hormone signaling pathway |
2件: 13, 227 |
| 97 | Eszopiclone | 1件: Eszopiclone; | D02624 |
16件: GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ |
7件: GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction |
3件: 6, 13, 46 |
| 98 | Ethanol | 7件: Andrographis paniculata (ethanol extract); Ethanol; Ethanol (96 per cent); Ethanol 96% gel; Ethanol 98% solution; Ethanol bp; Ethanol gel; | D00068
D02798
D04855
D06542 |
- |
- |
49件: 2, 11, 13, 14, 26, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 58, 61, 63, 64, 65, 66, 81, 84, 85, 86, 88, 95, 96, 97, 113, 145, 162, 164, 222, 224, 228, 251, 279, 280, 283, 284, 285, 288, 298, 299, 300, 331 |
| 99 | Ethinylestradiol | 1件: Ethinylestradiol; | D00554 |
1件: ESR1 |
8件: Breast cancer, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, Pathways in cancer, Prolactin signaling pathway, Proteoglycans in cancer, Thyroid hormone signaling pathway |
4件: 13, 46, 49, 299 |
| 100 | Etifoxine | 1件: Etifoxine; | D07320 |
- |
- |
1件: 13 |
| 101 | Etoposide | 2件: Carmustine, etoposide, cytarabine, and melphalan (beam); Etoposide; | D00125
D04107 |
2件: TOP2A, TOP2B |
1件: Platinum drug resistance |
11件: 11, 13, 14, 26, 28, 34, 60, 65, 85, 164, 331 |
| 102 | Evobrutinib | 2件: Evobrutinib; M2951 (other name: evobrutinib); | - |
- |
- |
3件: 13, 46, 49 |
| 103 | Febuxostat | 1件: Febuxostat; | D01206 |
1件: XDH |
5件: Caffeine metabolism, Drug metabolism - other enzymes, Metabolic pathways, Peroxisome, Purine metabolism |
3件: 2, 6, 13 |
| 104 | Ferric oxide | - | D04168 |
- |
- |
1件: 13 |
| 105 | Ferumoxytol | 1件: Ferumoxytol; | D04177 |
- |
- |
1件: 13 |
| 106 | Filgrastim | 6件: Ep2006 (filgrastim); Filgrastim; Filgrastim (g-csf); Filgrastim hexal; Filgrastim, alemtuzumab; Granulocyte colony-stimulating factor (filgrastim); | D03235 |
1件: CSF3R |
5件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer |
28件: 2, 6, 13, 16, 25, 26, 28, 34, 35, 36, 40, 41, 42, 45, 46, 49, 51, 60, 62, 65, 85, 96, 113, 164, 283, 284, 285, 331 |
| 107 | Fingolimod | 6件: 0,5 mg fingolimod; Fingolimod; Fingolimod (fty720); Fingolimod 0.5 mg; Fingolimod 1.25 mg; Fingolimod hydrochloride; | D10001 |
1件: S1PR1 |
3件: FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway |
4件: 2, 13, 14, 156 |
| 108 | Firategrast | 7件: Firategrast; Firategrast (usan approved name); Firategrast 150 mg; Firategrast 300 mg; Firategrast gastro-retentive solution; Firategrast immediate release tablet; Firategrast modified release tablet; | D06590 |
1件: ITGA4 |
14件: Arrhythmogenic right ventricular cardiomyopathy (ARVC), Cell adhesion molecules (CAMs), Dilated cardiomyopathy (DCM), ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Yersinia infection |
1件: 13 |
| 109 | Fish oil | 10件: Combination fish oil and borage seed oil; Combination of fish oil and colesevelam; Fish oil; Fish oil concentrate; Fish oil supplement; Fish oil, gamma-linolenic acid; Fish oil, rich in omega-3-acids; Fish oil,rich in omega 3 acids; Lipoic acid (la) with fish oil and la without fish oil; Omega-3 fatty acid fish oil supplement; | - |
- |
- |
7件: 13, 46, 49, 66, 96, 260, 299 |
| 110 | Fludarabine | 23件: Busulfan, cyclophosphamide, thymoglobulin, fludarabine (conditioning regimen); Busulfan, fludarabine and atg; Busulfan, fludarabine, & cyclophosphamide with immunosuppression with atg and cyclosporine.; Busulfan, fludarabine, atg, tli; Busulfan/fludarabine phosphate/tacrolimus/methotrexate/g-csf; Campath, fludarabine, cyclophosphamide; Cyclophosphamide, fludarabine; Cyclophosphamide, fludarabine , thymoglobulin; Cyclophosphamide, fludarabine, rabbit atg; Cyclophosphamide, fludarabine, thymoglobulin; Fludarabine; Fludarabine (flu); Fludarabine monophosphate; Fludarabine phosphate; Fludarabine phosphate 30 mg; Fludarabine phosphate 40 mg; Fludarabine, busulfan, thymoglobulin; Fludarabine, cyclophosphamide; Fludarabine, melphalan, thiotepa; Fludarabine/ melphalan; Fludarabine/busulfan; Sq fludarabine; Transplant preparative regimen of alemtuzumab, fludarabine, thiotepa, and melphalan; | D01907
D07966 |
1件: RRM1 |
5件: Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism |
17件: 13, 28, 36, 46, 49, 51, 60, 61, 62, 65, 85, 96, 164, 283, 284, 285, 326 |
| 111 | Fludeoxyglucose F-18 | 1件: Fludeoxyglucose f 18; | - |
- |
- |
8件: 6, 13, 34, 46, 53, 84, 127, 300 |
| 112 | Flumazenil | 4件: 11c-flumazenil; [11c]flumazenil; Flumazenil; Pet with 11c-flumazenil; | D00697 |
16件: GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ |
7件: GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction |
5件: 6, 13, 17, 18, 206 |
| 113 | Fluoxetine | 4件: Amitriptyline, fluoxetine and tramadol alone (control group); Fluoxetine; Fluoxetine hydrochloride; Sc recombinant growth hormone + amitriptyline, fluoxetine and tramadol (treated group); | D00326
D00823 |
1件: SLC6A4 |
2件: Serotonergic synapse, Synaptic vesicle cycle |
6件: 13, 17, 78, 86, 179, 206 |
| 114 | Flupirtine | 1件: Flupirtine; | D07978 |
- |
- |
1件: 13 |
| 115 | Flurbiprofen | 3件: Bms drug-drug interaction cocktail (montelukast, flurbiprofen, omeprazole, midazolam, and digoxin); Flurbiprofen; Montelukast, flurbiprofen, midazolam, digoxin, pravastatin and bms-986142; | D00330
D01475
D02290 |
2件: PTGS1, PTGS2 |
21件: Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway |
2件: 13, 46 |
| 116 | Folic acid | 5件: Folic acid; Folic acid or folate; Folic acid, vitamin b6, vitamin b12; Methotrexate and folic acid; Rituximab, mtx, folic acid; | D00070 |
- |
- |
11件: 6, 13, 46, 49, 62, 84, 86, 96, 97, 254, 284 |
| 117 | Fumaric Acid | 2件: Fumaric acid; Second-generation fumaric acid; | D02308 |
- |
- |
1件: 13 |
| 118 | GSK-2018682 | 2件: Gsk2018682; Gsk2018682 cd2 capsule; | - |
- |
- |
1件: 13 |
| 119 | GSK-239512 | 1件: Gsk239512; | - |
- |
- |
1件: 13 |
| 120 | Gabapentin | 3件: Gabapentin; Gabapentin prescriptions; Transdermal fentanyl matrix, gabapentin; | D00332 |
5件: CACNA2D1, CACNA2D2, CACNA2D3, CACNA2D4, SLC6A1 |
9件: Adrenergic signaling in cardiomyocytes, Arrhythmogenic right ventricular cardiomyopathy (ARVC), Cardiac muscle contraction, Dilated cardiomyopathy (DCM), GABAergic synapse, Hypertrophic cardiomyopathy (HCM), MAPK signaling pathway, Oxytocin signaling pathway, Synaptic vesicle cycle |
7件: 6, 13, 19, 70, 97, 226, 298 |
| 121 | Gadobenic acid | - | D04283
D08018 |
- |
- |
3件: 13, 86, 88 |
| 122 | Gadobutrol | 1件: Gadobutrol; | D07420 |
- |
- |
3件: 13, 22, 46 |
| 123 | Gadolinium | 6件: Gadolinium; Gadolinium contrast; Gadolinium for abdomen; Gadolinium for lower back; Gadolinium-based contrast; Standard gadolinium contrast; | - |
- |
- |
6件: 13, 34, 46, 58, 65, 305 |
| 124 | Gadoteric acid | 1件: Gadoteric acid; | D08007 |
- |
- |
2件: 13, 53 |
| 125 | Gadoteridol | 2件: Gadoteridol; Prohance (gadoteridol); | D01137 |
- |
- |
1件: 13 |
| 126 | Ginkgo biloba | 2件: Ginkgo biloba; Ginkgo biloba pills sig: 300mg/tid; | - |
- |
- |
3件: 6, 13, 90 |
| 127 | Ginseng | 4件: American ginseng; American ginseng extract ht-1001; Ginseng; Korean red ginseng; | D06772 |
- |
- |
3件: 13, 46, 53 |
| 128 | Glatiramer | 23件: 20mg/0.5ml glatiramer acetate; 40 mg glatiramer acetate; Cyclophosphamide/glatiramer acetate; Experimental glatiramer acetate; Glatiramer; Glatiramer acetate; Glatiramer acetate (copaxone®); Glatiramer acetate (db); Glatiramer acetate (ga); Glatiramer acetate (ga) 40 mg; Glatiramer acetate (ol); Glatiramer acetate 150mg enteric coated tablets; Glatiramer acetate 150mg enteric-coated (gastro-resistant) tablets; Glatiramer acetate 20 mg; Glatiramer acetate 20 mg, with mitoxantrone; Glatiramer acetate 20 mg/0.5 ml; Glatiramer acetate 40 mg; Glatiramer acetate injection with oral cetirizine hydrochloride; Glatiramer acetate with minocycline; Glatiramer acetate, (copaxone®); Glatiramer acetate, ifn-beta 1a (im), ifn-beta 1a (subcutaneous), and ifn-beta 1b; Glatiramer acetate, n-acetylcysteine; Human interferon beta-1a and glatiramer acetate; | D04318 |
20件: HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G |
32件: Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules (CAMs), Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease (IBD), Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis |
4件: 2, 13, 96, 156 |
| 129 | Glutamic Acid | - | D00007
D04341 |
- |
- |
1件: 13 |
| 130 | Glycerin | - | D00028 |
- |
- |
6件: 6, 13, 53, 265, 316, 317 |
| 131 | Gold | 3件: Gold; Gold nanocrystals; Sodium aurothiomalate (intramuscular gold); | - |
- |
- |
5件: 2, 6, 13, 46, 171 |
| 132 | Green olive | - | - |
- |
- |
3件: 13, 49, 53 |
| 133 | Guanabenz | 2件: Guanabenz; Guanabenz acetato; | D04375 |
3件: ADRA2A, ADRA2B, ADRA2C |
2件: Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway |
2件: 2, 13 |
| 134 | Histidine | 3件: Copper histidine; Histidine; L-histidine; | D00032 |
- |
- |
3件: 13, 169, 170 |
| 135 | Human interferon beta | 6件: Human interferon beta; Human interferon beta 1a (rebif); Human interferon beta-1a and glatiramer acetate; New formulation of rebif - human interferon beta-1a; Recombinant human interferon beta; Recombinant human interferon beta-1a; | - |
- |
- |
6件: 13, 14, 20, 26, 96, 97 |
| 136 | Human interleukin-2 | 2件: Human interleukin-2; Recombinant human interleukin-2 (rhil-2); | - |
- |
- |
14件: 2, 13, 35, 46, 49, 51, 55, 56, 63, 65, 95, 96, 97, 271 |
| 137 | Hydrochlorothiazide | 2件: Hydrochlorothiazide; Hydrochlorothiazide/amiloride; | D00340 |
- |
- |
3件: 13, 67, 225 |
| 138 | Hydroxychloroquine | 16件: Hydroxychloroquine; Hydroxychloroquine (z0188); Hydroxychloroquine + prednisone; Hydroxychloroquine high; Hydroxychloroquine higher dose; Hydroxychloroquine lower dose; Hydroxychloroquine or chloroquine; Hydroxychloroquine reduced; Hydroxychloroquine sulfate; Hydroxychloroquine sulphate; Leflunomide-sulfasalazine-hydroxychloroquine; Methotrexate + salazopyrine + hydroxychloroquine administration; Methotrexate-sulfasalazine-hydroxychloroquine; Sirolimus and hydroxychloroquine; Sulphasalazine + hydroxychloroquine or prednisolone; Versus hydroxychloroquine; | D08050 |
- |
- |
18件: 13, 41, 46, 48, 49, 53, 56, 66, 84, 89, 90, 96, 222, 234, 254, 271, 298, 299 |
| 139 | Hydroxytyrosol | 2件: Essential - hydroxytyrosol; Hydroxytyrosol; | - |
- |
- |
1件: 13 |
| 140 | Hydroxyurea | 1件: Hydroxyurea; | D00341 |
1件: RRM2 |
6件: Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism, p53 signaling pathway |
8件: 3, 13, 19, 20, 65, 85, 86, 284 |
| 141 | Ibudilast | 1件: Ibudilast; | D01385 |
8件: CYSLTR1, PDE3A, PDE3B, PDE4A, PDE4B, PDE4C, PDE4D, PTGIR |
16件: Apelin signaling pathway, Calcium signaling pathway, Glucagon signaling pathway, Insulin signaling pathway, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parathyroid hormone synthesis, secretion and action, Platelet activation, Progesterone-mediated oocyte maturation, Purine metabolism, Regulation of lipolysis in adipocytes, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
2件: 2, 13 |
| 142 | Ibuprofen | 5件: Ibuprofen; Ibuprofen 200mg; Ibuprofen pch tablet 600mg; Rebif new formulation + ibuprofen prn; Rebif new formulation + prophylactic ibuprofen; | D00126
D01122
D04490
D06606 |
2件: PTGS1, PTGS2 |
21件: Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway |
6件: 13, 46, 65, 113, 271, 299 |
| 143 | Idebenone | 2件: Idebenone; Idebenone 150 mg film-coated tablets; | D01750 |
- |
- |
4件: 6, 13, 113, 302 |
| 144 | Imatinib | 6件: Bevacizumab (avastin) and imatinib mesylate (gleevec); Imatinib; Imatinib mesilate; Imatinib mesylate; Imatinib mesylate (gleevec); Imatinib mesylate 400mg capsule; | D01441
D08066 |
3件: ABL1, KIT, PDGFRA |
32件: Acute myeloid leukemia, Axon guidance, Breast cancer, Calcium signaling pathway, Cell cycle, Central carbon metabolism in cancer, Choline metabolism in cancer, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocytosis, ErbB signaling pathway, Focal adhesion, Gap junction, Glioma, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Shigellosis, Viral myocarditis |
11件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 89, 162 |
| 145 | Immune Globulin Human | - | - |
- |
- |
20件: 2, 11, 13, 14, 17, 18, 35, 38, 39, 43, 45, 49, 50, 51, 63, 65, 85, 164, 296, 309 |
| 146 | Indian frankincense | - | - |
- |
- |
1件: 13 |
| 147 | Inosine | 2件: 1) inosine 5'-monophosphate; Inosine; | D00054 |
- |
- |
4件: 2, 6, 13, 17 |
| 148 | Interferon beta-1a | 28件: Avonex (interferon beta 1a); Avonex (interferon beta-1a), biogen idec ltd; Bcd-033 (interferon beta 1a); Bg9418 (interferon beta-1a); Human interferon beta 1a (rebif); Human interferon beta-1a and glatiramer acetate; Interferon beta 1a; Interferon beta 1a 30 ug im once weekly; Interferon beta 1a, oral doxycycline; Interferon beta-1a; Interferon beta-1a (avonex); Interferon beta-1a (avonex®); Interferon beta-1a (current approved manufacturing process invloving fbs); Interferon beta-1a (new process, manufactured without fbs); Interferon beta-1a (rebif); Interferon beta-1a 30 µg; Interferon beta-1a fbs-free/hsa-free, rnf; Interferon beta-1a hsa+ biosimilar; Interferon beta-1a hsa-free biosimilar; Interferon beta-1a original; Interferon beta1a; New formulation of rebif - human interferon beta-1a; Pegylated interferon beta-1a; Rebif (interferon beta 1a); Rebif (interferon beta-1a); Rebif (interferon beta-1a), merck serono europe ltd; Recombinant human interferon beta-1a; Sc interferon beta-1a; | D04554 |
2件: IFNAR1, IFNAR2 |
17件: Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway |
5件: 13, 14, 26, 96, 97 |
| 149 | Interferon beta-1b | 21件: Betaferon® (interferon beta-1b); Betaseron (interferon beta-1b, bay86-5046); Betaseron (interferon beta-1b, bay86-5046), bayer healthcare ag; Extavia (interferon beta-1b), novartis pharma ag; Interferon beta 1b; Interferon beta 1b (betaseron, bay86-5046); Interferon beta-1b; Interferon beta-1b (betaferon, bay 86-5046); Interferon beta-1b (betaferon, bay86-5046); Interferon beta-1b (betaferon/betaseron, bay86-5046); Interferon beta-1b (betaferon®, bay 86-5046); Interferon beta-1b (betaseron, bay86-5046); Interferon beta-1b (betaseron, betaferon, bay86-5046); Interferon beta-1b (pf530, betaferon); Interferon beta-1b and tacrolimus; Interferon beta-1b group; Interferon beta-1b, (betaseron bay86-5046); Interferon beta-1b/atorvastatin group; Msdmds other than betaseron (interferon beta-1b, bay86-5046); Recombinant interferon beta-1b; Sc interferon beta-1b; | D00746 |
2件: IFNAR1, IFNAR2 |
17件: Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway |
1件: 13 |
| 150 | Iron | 14件: Injection of iron; Iron; Iron chelating agents; Iron dextran; Iron oxide; Iron sucrose; Iron sulphate; Iron sulphate 200mg coated tablets; Iron supplement; Iron supplement 300-600 mg/day; Iron(iii)- hydroxide dextran complex; Oral iron; Ultra small particles of iron oxide (uspio); Ultrasmall particles of iron oxide; | - |
- |
- |
7件: 13, 62, 86, 96, 97, 254, 284 |
| 151 | Isopropyl alcohol | - | D00137 |
- |
- |
10件: 13, 46, 58, 84, 96, 97, 269, 271, 279, 298 |
| 152 | Isoxaflutole | - | - |
- |
- |
8件: 5, 6, 13, 18, 81, 113, 149, 299 |
| 153 | Isoxsuprine | 2件: Isoxsuprine; Isoxsuprine hydrochloride; | D08092 |
1件: ADRB2 |
8件: Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway |
1件: 13 |
| 154 | Ixazomib | 3件: Ixazomib; Ixazomib (ninlaro®) capsules; Ixazomib citrate; | D10130 |
1件: PSMB5 |
1件: Proteasome |
4件: 13, 16, 28, 61 |
| 155 | Ketamine | 3件: Ketamine; S-ketamine; S-ketamine & midazolam; | D00711
D08098 |
5件: GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D |
17件: Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Rap1 signaling pathway, Ras signaling pathway, Systemic lupus erythematosus, cAMP signaling pathway |
6件: 6, 13, 70, 113, 156, 215 |
| 156 | Ketoconazole | 2件: Dimebon + ketoconazole; Ketoconazole; | D00351 |
1件: CYP17A1 |
6件: Cortisol synthesis and secretion, Cushing syndrome, Metabolic pathways, Ovarian steroidogenesis, Prolactin signaling pathway, Steroid hormone biosynthesis |
3件: 8, 13, 75 |
| 157 | L-Alanine | 1件: L-alanine; | D00012 |
- |
- |
3件: 13, 298, 299 |
| 158 | L-Cysteine | - | D00026
D02326 |
- |
- |
9件: 6, 13, 19, 84, 85, 88, 90, 254, 296 |
| 159 | L-Lysine | 2件: L-lysine; L-lysine-n-acetylcysteinate; | D02304 |
- |
- |
4件: 13, 97, 228, 299 |
| 160 | Lactose | 3件: Lactose; Lactose in water; Lactose monohydrate; | D00046
D03226 |
- |
- |
6件: 2, 6, 13, 97, 228, 310 |
| 161 | Lamotrigine | 3件: Lamotrigine; Lamotrigine dispers; Lamotrigine extended release tablets; | D00354 |
5件: SCN1A, SCN2A, SCN3A, SCN5A, SCN9A |
3件: Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Taste transduction |
3件: 13, 34, 114 |
| 162 | Laquinimod | 8件: Laquinimod; Laquinimod 0.6; Laquinimod 1.2; Laquinimod capsules 0.3 mg; Laquinimod capsules 0.6 mg; Laquinimod cápsulas 0.5 mg; Laquinimod sodium (usan); Laquinimod tablets 0.3 mg; | - |
- |
- |
4件: 8, 13, 49, 96 |
| 163 | Levetiracetam | 1件: Levetiracetam; | D00709 |
1件: SV2A |
1件: ECM-receptor interaction |
4件: 2, 4, 6, 13 |
| 164 | Levocarnitine | 4件: Levocarnitine; Levocarnitine propyl hydrochloride; Valproate, levocarnitine; Valproic acid and levocarnitine; | D02030
D02176
D04713 |
- |
- |
10件: 3, 5, 13, 53, 58, 96, 97, 265, 298, 316 |
| 165 | Levoleucovorin | - | D04715 |
- |
- |
1件: 13 |
| 166 | Levonorgestrel | 1件: Levonorgestrel; | D00950 |
1件: PGR |
4件: Breast cancer, Estrogen signaling pathway, Oocyte meiosis, Progesterone-mediated oocyte maturation |
1件: 13 |
| 167 | Lidocaine | 8件: 5% lidocaine/5 mg/ml estradiol compound cream; Alkalinized lidocaine-heparin; Bladder instillation with heparin/ lidocaine; Lidocaine; Lidocaine injection 2%; Lidocaine patch 5%; Lidocaine releasing intravesical system - liris®; Local anesthesia (lidocaine hydrochloride); | D00358
D02086
D08127 |
5件: SCN1A, SCN2A, SCN3A, SCN5A, SCN9A |
3件: Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Taste transduction |
10件: 6, 13, 46, 84, 86, 97, 168, 226, 231, 256 |
| 168 | Linoleic acid | 2件: Linoleic acid; Linoleic acid/oleic acid; | - |
- |
- |
1件: 13 |
| 169 | Liothyronine | 3件: Liothyronine; Liothyronine i 131; Liothyronine sodium; | D01011
D08128 |
2件: THRA, THRB |
2件: Neuroactive ligand-receptor interaction, Thyroid hormone signaling pathway |
3件: 13, 78, 212 |
| 170 | Lipoic Acid | 8件: Alpha lipoic acid; Alpha-lipoic acid; Alpha-lipoic acid and l-acetyl carnitine; Lipoic acid; Lipoic acid (la) with fish oil and la without fish oil; Lipoic acid and omega-3 fatty acids; Oral lipoic acid (la); R lipoic acid; | D00048
D00086 |
- |
- |
5件: 2, 5, 13, 14, 20 |
| 171 | Lisdexamfetamine | 2件: Lisdexamfetamine; Lisdexamfetamine sulfate; | D08130 |
2件: SLC6A2, SLC6A3 |
6件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Parkinson disease, Synaptic vesicle cycle |
1件: 13 |
| 172 | Lithium carbonate | 1件: Lithium carbonate; | D00801 |
- |
- |
8件: 2, 5, 7, 8, 13, 17, 19, 127 |
| 173 | Loperamide | 1件: Loperamide; | D00729
D07113
D08144 |
3件: OPRD1, OPRK1, OPRM1 |
5件: Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway |
2件: 13, 97 |
| 174 | Loratadine | 1件: Loratadine; | D00364 |
1件: HRH1 |
3件: Calcium signaling pathway, Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction |
3件: 6, 13, 46 |
| 175 | Losartan | 8件: Lisinopril, losartan, and atorvastatin; Losartan; Losartan and atenolol or propranolol; Losartan bluefish 50 mg; Losartan potasico; Losartan potassium; Losartan tablets & qingremoshen granule; Sildenafil and losartan; | D00357
D08146 |
1件: AGTR1 |
14件: AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway |
18件: 13, 17, 19, 46, 58, 66, 67, 85, 96, 97, 98, 113, 164, 167, 179, 215, 222, 299 |
| 176 | Lubiprostone | 1件: Lubiprostone; | D04790 |
1件: CLCN2 |
1件: Mineral absorption |
4件: 6, 13, 290, 299 |
| 177 | MK-0812 | 2件: Mk0812; Mk0812 / duration of treatment: 12 weeks; | - |
- |
- |
2件: 13, 46 |
| 178 | Magnesium | 16件: (s)-4,5-dihydro-2-[2-hydroxy-3-(3,6,9-trioxadecyloxy)phenyl]-4-methyl-4-thiazolecarboxylate magnesium hydroxide; (s)-4,5-dihydro-2[hydroxy-3-(3,6,9-trioxadecyloxy)phenyl]-4-methyl-4-thiazolecarboxylate magnesium hydroxide; Magnesium; Magnesium citrate; Magnesium gluconate; Magnesium hydroxide; Magnesium oxide; Magnesium sulfate; Mineral boost (magnesium); Nexium (esomeprazole magnesium); Omeprazole magnesium; Saroglitazar magnesium 2 mg; Saroglitazar magnesium 4 mg; Sodium picosulfate, magnesium oxide and citric acid; Sodium picosulfate/magnesium citrate laxative; Sulfate, magnesium; | - |
- |
- |
15件: 6, 11, 13, 46, 64, 93, 97, 166, 225, 235, 284, 291, 296, 297, 298 |
| 179 | Maltodextrin | 3件: Maltodextrin; Maltodextrin fiber supplement; Resistant maltodextrin; | D02329 |
- |
- |
4件: 6, 13, 96, 97 |
| 180 | Mangafodipir | 2件: Mangafodipir; Mangafodipir (teslascan); | D08262 |
- |
- |
2件: 13, 58 |
| 181 | Mannose | 3件: D mannose; Mannose; Recombinant human a-glucosidase conjugated with multiple copies of synthetic bis-mannose-6-phosphate-tetra-mannose glycan (neogaa); | - |
- |
- |
2件: 13, 256 |
| 182 | Masitinib | 10件: Masitinib; Masitinib (3.0); Masitinib (4.5); Masitinib (6.0); Masitinib (ab1010); Masitinib 100mg; Masitinib 200mg; Masitinib 3 mg; Masitinib 6.0 mg; Masitinib mesylate; | D10229 |
1件: KIT |
11件: Acute myeloid leukemia, Breast cancer, Central carbon metabolism in cancer, Hematopoietic cell lineage, MAPK signaling pathway, Melanogenesis, PI3K-Akt signaling pathway, Pathways in cancer, Phospholipase D signaling pathway, Rap1 signaling pathway, Ras signaling pathway |
6件: 2, 5, 6, 13, 46, 96 |
| 183 | Medical Cannabis | - | - |
- |
- |
6件: 2, 6, 13, 90, 96, 97 |
| 184 | Melatonin | 10件: 3 mg melatonin; 5 mg melatonin; Circadin ( inn= melatonin); Diazepam, melatonin; Dtr melatonin (nih cc pds); Hourly dosing of the nychtemeral secretion of melatonin; Melatonin; Melatonin cr; Melatonin pr; Melatonin(circadin®); | D08170 |
2件: MTNR1A, MTNR1B |
2件: Circadian entrainment, Neuroactive ligand-receptor interaction |
8件: 6, 13, 46, 49, 90, 97, 144, 202 |
| 185 | Melphalan | 8件: Carmustine, etoposide, cytarabine, and melphalan (beam); Fludarabine, melphalan, thiotepa; Fludarabine/ melphalan; Melphalan; Melphalan hydrochloride; Melphalan, thalidomide and dexamethasone; Propylene glycol-free melphalan hydrochloride; Transplant preparative regimen of alemtuzumab, fludarabine, thiotepa, and melphalan; | D00369 |
- |
- |
14件: 11, 13, 14, 19, 20, 28, 60, 62, 65, 96, 164, 234, 284, 285 |
| 186 | Memantine | 3件: Memantine; Memantine (ebixa); Memantine hydrochloride; | D04905
D08174 |
5件: GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D |
17件: Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Rap1 signaling pathway, Ras signaling pathway, Systemic lupus erythematosus, cAMP signaling pathway |
7件: 2, 6, 8, 13, 49, 127, 205 |
| 187 | Metformin | 12件: 750 mg metformin and 7.5 g l-citrulline daily p.o.; Glucophage (metformin); L-citrulline and metformin & l-citrulline; Metformin; Metformin (generic); Metformin 500mg; Metformin and metformin & l-citrulline; Metformin hcl; Metformin hydrochloride; Metformin/cp-690,550; Pioglitazone or metformin; Sitagliptin and metformin; | D00944
D04966 |
2件: PRKAA1, PRKAA2 |
19件: AMPK signaling pathway, Adipocytokine signaling pathway, Apelin signaling pathway, Autophagy - animal, Circadian rhythm, Fluid shear stress and atherosclerosis, FoxO signaling pathway, Glucagon signaling pathway, Hypertrophic cardiomyopathy (HCM), Insulin resistance, Insulin signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Non-alcoholic fatty liver disease (NAFLD), Oxytocin signaling pathway, PI3K-Akt signaling pathway, Thermogenesis, Tight junction, mTOR signaling pathway |
17件: 6, 13, 46, 49, 67, 75, 77, 81, 86, 113, 158, 206, 225, 233, 265, 285, 299 |
| 188 | Methamidophos | - | - |
- |
- |
12件: 2, 11, 13, 19, 46, 49, 58, 70, 85, 98, 298, 300 |
| 189 | Methotrexate | 81件: Abatacept (aba) + methotrexate (mtx), double-blind (db); Abatacept + methotrexate; Adalimumab with methotrexate; Azathioprine or methotrexate; Bms-582949 and methotrexate; Busulfan/fludarabine phosphate/tacrolimus/methotrexate/g-csf; Certolizumab pegol + methotrexate (mtx); Clobetasol propionate + methotrexate; Cp-690,550 + methotrexate; Cyclosporin, methotrexate (gvhd prophylaxis); Early immunosuppressants (azathioprine, methotrexate); Etanercept + methotrexate; Etanercept , methotrexate; Etanercept, methotrexate, prednisolone; Immunosuppressive regime (azathioprine, mycophenolate mofetil or methotrexate); Infliximab + methotrexate (mtx); Infliximab, methylprednisolone, methotrexate; Intrathecal methotrexate; Methotrexate; Methotrexate 'lederle' 2,5mg tablets; Methotrexate 'lederle' 2.5mg tablets; Methotrexate (metoject® prefilled pen); Methotrexate (mtx); Methotrexate + biologic administration; Methotrexate + infliximab; Methotrexate + methylprednisolone; Methotrexate + salazopyrine + hydroxychloroquine administration; Methotrexate - amneal; Methotrexate - dava; Methotrexate - delay; Methotrexate - etanercept - prednisolone arm; Methotrexate - immediate; Methotrexate 2.5 mg; Methotrexate 2.5 mg tablets; Methotrexate 2.5mg tablets; Methotrexate 2.5mg tablets bp; Methotrexate 25 mg; Methotrexate 50mg/ml solution for injection, pre-filled syringe; Methotrexate and folic acid; Methotrexate as methotrexate disodium; Methotrexate bellon; Methotrexate bellon 25mg/ml; Methotrexate capsules; Methotrexate disodium; Methotrexate lachema 5inj. sol; Methotrexate pfizer 2,5 mg tabletter; Methotrexate placebo; Methotrexate plus enbrel or enbrel alone; Methotrexate plus erb-041 for 12 weeks; Methotrexate plus sulfasalazine; Methotrexate pre-filled pen; Methotrexate prefilled pen; Methotrexate prefilled syringe; Methotrexate sodium; Methotrexate sodium 2.5mg tablets; Methotrexate sodium tablets 2.5 mg; Methotrexate treatment; Methotrexate(mtx); Methotrexate(mtx) administration is at the discretion of the rheumatologist and no tradename is fixed by the protocol.; Methotrexate(necessary); Methotrexate*100cpr 2,5mg; Methotrexate, leucovorin and bms-986142; Methotrexate,adalimumab; Methotrexate-lachema; Methotrexate-sulfasalazine-hydroxychloroquine; Methotrexate® 2.5 mg tablets; Mp-435(dose1) + methotrexate; Mycophenolate mofetil,methotrexate; Oral methotrexate; Phase 1: methotrexate; Response to anakinra associated with methotrexate; Response to infliximab associated with methotrexate; Stable weekly dose of methotrexate; Tacrolimus with methotrexate; Tasocitinib plus methotrexate; Tocilizumab + methotrexate(mtx); Tocilizumab+methotrexate(mtx); Tofacitinib with methotrexate; Tofacitinib without methotrexate; Treatment with systemic therapy (methotrexate); Urine samples taken to measure methotrexate and its major metabolite 7-oh-methotrexate level; | D00142
D02115 |
2件: DHFR, DHFR2 |
4件: Antifolate resistance, Folate biosynthesis, Metabolic pathways, One carbon pool by folate |
33件: 11, 13, 19, 34, 35, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, 97, 162, 164, 172, 256, 271, 284, 285, 326, 331 |
| 190 | Methylphenidate | 11件: D-methylphenidate; Methylphenidate; Methylphenidate (mpd); Methylphenidate (overencapsulated); Methylphenidate 10mg tablets; Methylphenidate hydrochloride; Methylphenidate modified release; Methylphenidate modified release 20 mg; Methylphenidate modified release 30 mg; Methylphenidate modified release 40 mg; Methylphenidate, fluoxetin, risperidone; | D01296
D04999 |
2件: SLC6A2, SLC6A3 |
6件: Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Parkinson disease, Synaptic vesicle cycle |
7件: 6, 13, 34, 84, 113, 179, 206 |
| 191 | Methylprednisolone | 29件: Administration of rituximab and methylprednisolone; Corticosteroid treatment (methylprednisolone or prednisolone); Cyclophosphamide, azathioprine,prednisone,methylprednisolone; Infliximab, methylprednisolone, methotrexate; Intravenous (i.v.) methylprednisolone 1000 mg, total 9; Intravenous methylprednisolone; Iv methylprednisolone; Iv methylprednisolone (steroids); Megadose oral methylprednisolone; Methotrexate + methylprednisolone; Methylprednisolone; Methylprednisolone (drug); Methylprednisolone (mp); Methylprednisolone (mp) or prednisone (pred); Methylprednisolone (or other glucocorticoid); Methylprednisolone bolus iv 15 mg/kg/d for 3 days.; Methylprednisolone hemisuccinate; Methylprednisolone iv; Methylprednisolone mylan générique; Methylprednisolone or budesonide; Methylprednisolone or prednisolone; Methylprednisolone pulse; Methylprednisolone sodium hemisuccinate; Methylprednisolone sodium succinate; Methylprednisolone(intravenously in the 1st-2nd-3rd month ); Methylprednisolone(intravenously in the 1st-3rd-5th month); Oral 5-asa+/-topical 5-asa+iv corticosteroids / po methylprednisolone; Prednisone (and methylprednisolone); Prednisone, methylprednisolone,cyclophosphamides; | D00407
D00751
D00979
D05000
D05001
D05002 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
36件: 2, 13, 25, 26, 35, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 51, 60, 63, 64, 65, 66, 83, 84, 86, 96, 97, 145, 164, 220, 222, 224, 271, 283, 284, 285, 296 |
| 192 | Methylprednisolone hemisuccinate | 1件: Methylprednisolone hemisuccinate; | D05000 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
2件: 13, 97 |
| 193 | Midazolam | 6件: Bms drug-drug interaction cocktail (montelukast, flurbiprofen, omeprazole, midazolam, and digoxin); Midazolam; Midazolam 2 mg; Midazolam 3 mg; Montelukast, flurbiprofen, midazolam, digoxin, pravastatin and bms-986142; S-ketamine & midazolam; | D00550
D00696
D05028 |
16件: GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ |
7件: GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction |
10件: 2, 3, 6, 13, 46, 70, 96, 97, 231, 298 |
| 194 | Minocycline | 7件: Combination of minocycline and mtx or mtx alone; Glatiramer acetate with minocycline; Lovastatin, then minocycline/lovastatin; Minocycline; Minocycline 100 mg film-coated tablets; Minocycline hydrochloride; Minocycline, then minocycline/lovastatin; | D00850
D05045 |
- |
- |
14件: 2, 6, 8, 13, 46, 84, 85, 90, 94, 162, 201, 206, 280, 299 |
| 195 | Mirabegron | 1件: Mirabegron; | D09535 |
1件: ADRB3 |
7件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Thermogenesis, cGMP-PKG signaling pathway |
3件: 6, 13, 226 |
| 196 | Mitoquinone | 1件: Mitoquinone; | - |
- |
- |
1件: |